---
layout: post
title: "Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics; Draft Guidance for Industry; Availability"
date: 2026-02-05 18:59:37 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-13606
original_published: 2022-06-27 00:00:00 +0000
significance: 8.00
---

# Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:59 UTC
**Source:** Federal Register
**Original Published:** June 27, 2022 00:00 UTC
**Document Number:** 2022-13606

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics." This draft guidance describes FDA's recommendations regarding clinical pharmacology considerations during the development of oligonucleotide therapeutics, including characterizing the potential for QT interval prolongation, performing immunogenicity risk assessment, characterizing the impact of hepatic and renal impairment, and assessing the potential for drug-drug interactions. The intent of this guidance is to assist industry in the conduct of these studies.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/06/27/2022-13606/clinical-pharmacology-considerations-for-the-development-of-oligonucleotide-therapeutics-draft)
- API: https://www.federalregister.gov/api/v1/documents/2022-13606

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
